You have not verified your Email yet. Please verify your Email to create alerts
Verify EmailGLAND
Gland Pharma
|
Caplin Point Lab
|
Gufic Biosciences
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
66.0 . | n/a | n/a |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
346.0 . | 38.0 . | n/a |
Number of ANDA's Approved By USFDA
|
279.0 . | 25.0 . | n/a |
Unclassified
|
|||
R&D as a % of Total Sales
|
4.8 % | 4.04 % | 1.06 % |
API Capacity
|
11000.0 Kg/Year | n/a | n/a |
Financials
|
|||
5 yr Average ROE
|
16.21 % | 22.25 % | 26.14 % |
5yr average Equity Multiplier
|
1.1 | 1.17 | 2.92 |
5yr Average Asset Turnover Ratio
|
0.54 | 0.76 | 1.09 |
5yr Avg Net Profit Margin
|
26.8 % | 24.85 % | 9.03 % |
Price to Book
|
3.49 | 4.81 | 7.88 |
P/E
|
44.05 | 22.8 | 36.57 |
5yr Avg Cash Conversion Cycle
|
141.92 Days | 64.48 Days | -18.02 Days |
Inventory Days
|
117.9 Days | 54.23 Days | 77.22 Days |
Days Receivable
|
97.99 Days | 88.48 Days | 81.36 Days |
Days Payable
|
98.36 Days | 76.0 Days | 141.41 Days |
5yr Average Interest Coverage Ratio
|
245.99 | 513.03 | 10.3 |
5yr Avg ROCE
|
21.37 % | 27.4 % | 33.27 % |
5yr Avg Operating Profit Margin
|
39.34 % | 34.96 % | 17.37 % |
5 yr average Debt to Equity
|
0.0 | 0.01 | 0.73 |
5yr CAGR Net Profit
|
0.21 % | 16.34 % | 29.43 % |
5yr Average Return on Assets
|
14.66 % | 19.05 % | 10.12 % |
Shareholdings
|
|||
Promoter Holding
|
57.86 % | 70.62 % | 72.51 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.39 % | 1.59 % | 6.76 % |
Change in Mutual Fund Holding (3 Yrs)
|
12.81 % | 0.03 % | -6.16 % |
Gland Pharma
|
Caplin Point Lab
|
Gufic Biosciences
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Distribution Channel
|
Distribution Channel
|
Distribution Channel
|
-
|